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Introduction: Chronic cough is a common clinical problem and there is a shortage of effective treat-
ments for it. Within the group of transient receptor potential ion channels a receptor for the cooling
substancementholhasbeen identified.This studyaimed toassesswhetherpre-inhalationofdissolved,
nebulisedmenthol could increase capsaicin cough thresholds and influence spirometric values.
Methods: Fourteenpatientswithchroniccoughandairwaysensitivity toenvironmental irritantsand15
control subjectswere testedonthreeoccasions. Eachone inhaleda1mLofnebulisedmenthol solution
of0.5%or1%orplacebo(salinewith0.05%menthol)ateachvisit inarandomizedanddouble-blindorder.
They were then provoked by capsaicin inhalation.
Results: Patients’ cough thresholds differed significantly from the controls’ on all three provocations
(P< 0.0001). After inhalation of 1%menthol, the patients’ cough thresholds were significantly higher
(P< 0.02) compared to after placebo inhalation and to after 0.5%menthol inhalation (P< 0.05). The
patients’ peak inspiratory flows were significantly reduced after inhalation of the placebo (saline)
(P< 0.05) but not after inhalation of 0.5% or 1%menthol. Forced inspiratory flows 50% were lowered
after inhalationofplaceboandof0.5%menthol(P<0.05)butnotafter1%menthol.Amongthecontrols,
forced inspiratory flows 50% were lowered after only placebo inhalation (P< 0.05).
Conclusions: In patients with chronic cough, pre-inhalation of menthol reduces cough sensitivity to
inhaled capsaicin and influences inspiratory flows. The findings may provide scientific support for the
common practice of using menthol as a reliever for variant airway discomfort. The use of menthol in
different cigarette brands could be questioned since it could conceal the natural irritation following
smoking.
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odorous chemicals and scents, but without asthma (bronchialCough is one of themost common causes to seekmedical help
in the Western world.1 When it persists for more than 2
months, it is regarded as chronic, though the definition of
“chronic cough” varies in the literature.2 Thepathophysiology
behind coughing is fairly well understood in a number of
conditions, although it is not always possible to attribute
a persistent cough to an airway disease or any other medical
disorder. In some cases, chronic cough is related to reflux and
indigestion3 and some authors claim an upper airway cough
syndromeasacommonreasonforenduring cough.4 Still, there
remains a group of patients with no obvious explanation for
their coughing; these patients are often described as pre-
senting with chronic idiopathic cough.5,6 In chronic cough,
both labelled as idiopathic and with an evident cause as
asthma or chronic obstructive pulmonary disease (COPD),
augmented cough sensitivity to inhaled capsaicin is often
present and may mirror a general up-regulation of the cough
reflex, described by the term cough hypersensitivity
syndrome.7e9
\Menthol (C10H20O) is contained in non-prescription
products for short-term relief of minor mouth, nasal and
throat irritation, for example in lip balms, cough medicines
and nasal sprays.10 In addition, it is used as an additive in
certain cigarette brands, both for flavour and to reduce and
“hide” the throat and sinus irritation caused by smoking.11,12
The sensation of cold evoked by menthol was explained by
the recently identified transient receptor potential melastin
8 (TRPM8) receptor, which is triggered by cool temperatures
and menthol.13e15 The increasing knowledge of the role of
transient receptor potential (TRP) ion channels in respiratory
diseases and of the TRPM8 may indicate a function for
menthol in cough treatment.16
Several studies have provided evidence of a condition
called airway sensory hyperreactivity (SHR), which is distinct
from asthma, COPD, or allergy. SHR patients with cough and
pronounced airway sensitivity to environmental irritants like
434Table 1 Demographic data of patients with chronic cough.
Patient
no
Sex Age FEV1% of
predicted value
1 F 61 116
2 F 52 119
3 F 54 81
4 F 35 70
5 F 65 100
6 F 54 126
7 F 50 116
8 F 53 108
9 F 28 91
10 M 62 103
11 F 44 98
12 F 36 117
13 F 64 100
14 M 58 102obstruction) or allergy, have increased cough sensitivity to
inhaled capsaicin.17,18
The aim of this study was to evaluate any influence of
inhaled, nebulised menthol on capsaicin cough sensitivity
and on lung function and inspiratory flow values in patients
with chronic cough and SHR in comparison with healthy
control subjects.
Methods
Subjects
Fourteen non-smoking patients (12 women and 2 men) were
consecutively selected from the Asthma and Allergy
Outpatient Clinic at Sahlgrenska University hospital Goth-
enburg Sweden, during 2010. Their mean age was 51 years
[95% confidence interval (CI): 45e58] and they had a history
of at least one year (mean 14; 95% CI: 10e18) of cough and
other airway symptoms induced by environmental irritants.
They had a negative skin prick test testing ten of the most
common respiratory allergens in Sweden, a negative
methacholine test in accordance with international guide-
lines,19 and no signs of spirometric reversibility or vari-
ability in lung function. Further they had no diagnosis or
symptoms of gastro-oesophageal reflux. They were
screened with a capsaicin inhalation cough test20 and with
questionnaires on airway symptoms in response to chem-
icals and scents21 and all had pronounced airway symptoms,
including cough, induced by such items. After fulfilling the
criteria for a positive capsaicin inhalation cough test and
reaching the cut-off limit for the diagnosis of SHR,18,20 the
patients were consecutively asked to take part in the study.
Demographic data are shown in Table 1.
The control group consisted of 15 non-smoking individ-
uals, 13 women and 2 men, and was recruited from among
hospital workers and the researchers’ friends and relatives.Duration of
disease (years)
Inducing factors
15 Chemical irritants, exercise
23 Chemical irritants, exercise
7 Chemical irritants, exercise
20 Chemical irritants, exercise
10 Chemical irritants
16 Chemical irritants, exercise,
cold air
24 Chemical irritants, cold air
10 Chemical irritants, exercise,
cold air
7 Chemical irritants, exercise,
cold air
6 Chemical irritants, cold air
15 Chemical irritants, cold air
1 Chemical irritants, exercise,
cold air
25 Chemical irritants
15 Chemical irritants, cold air
Inhaled menthol reduces the capsaicin cough response 435Their mean age was 52 years (95% CI: 46e58). They were to
consider themselves as healthy, report no airway symptoms
and use no airway-related drugs. No further physical
examination was done.
The participants were not allowed to be treated with
angiotensin converting enzyme inhibitors or any medication
for gastro-oesophageal reflux. Pregnancy and breastfeeding
were exclusion criteria.
Written informed consent was obtained from all patients
and controls after they were provided with verbal and
written information. The Regional Ethical Review Board of
Gothenburg, Sweden approved the study.
Study design
All participants visited the clinic on three occasions with
about one week’s interval apart each occasion. At each visit
they inhaled a 1 mL menthol solution of one of two
concentrations or a solution to represent placebo as near as
possible (saline with 0.05% menthol added so the partici-
pants couldn’t guess which was a placebo by the lack of
menthol). After the participant rested for five minutes,
a capsaicin inhalation provocation was performed.
The cough thresholds of all study participants were
registered manually during the provocations by the same
investigator. Cough was defined as the characteristic sound
that follows a forced expiratory effort against a closed
glottis and distinguished from other sounds such as clearing
the throat22,23 by a discretionary decision of the investi-
gator upon observation of the subjects.
Menthol inhalation
As noted, before each capsaicin test, a pre-inhalation was
given in a double-blind and randomized fashion, of either
1 mL 0.05% menthol (placebo), or 1 mL of 0.5% or 1%
menthol.
Five gram of pure (99%) solid menthol (SigmaeAldrich,
Sweden AB, Stockholm, M2772) was dissolved in 5 mL 99.5%
ethanol and 5 mL Tween-80 (SigmaeAldrich, Sweden AB,
Stockholm, P1754) providing a stock solution of 50%
menthol. Menthol solutions of 0.05%, 0.5% and 1% were
prepared from this stock solution with 0.9% saline (9 mg/
mL).
Doses were administrated from a compressed air driven
sidestream nebulizer (MedicAid Pro, Sussex, UK) controlled
by an aerosol provocation system (APS version 5,02 soft-
ware, Viasys Healthcare GmbH, Hoechberg, Germany). The
nebulizers’ output was 240 mg/min and the mass median
particle diameter 3.2 mm. Each dose of 1 mL was inhaled
through a mouthpiece, without a nose clip, by tidal volume
breathing to completion, or for a maximum of 4 min, fol-
lowed by 5 min of rest before the capsaicin provocation.
Capsaicin cough provocation
A stock solution of capsaicin (SigmaeAldrich, Sweden AB,
Stockholm, M2028) [1 mmol/L in ethanol (99.5%)] was
prepared and then dissolved in 0.9% saline to provide
a stock solution of 512 mmol/L capsaicin. Fresh serial dilu-
tions were prepared from stock solution, using salinediluent to produce doubling concentrations from 0.5 to
512 mmol/L.
Doses were administrated using the nebulizer described
above (MedicAid Pro, Sussex, UK).
The capsaicin cough challenge was performed in accor-
dance with the ERS guidelines23 using the single breath
method. The duration of aerosol delivery was programmed to
0.4 s, thereby providing 0.0016 mL per breath. The subjects
inhaled, without a nose clip, three single vital capacity
breathes before the capsaicin solutionwas given in the fourth
inhalation. Doubling doses were given every minute and the
concentration of capsaicin causing five (C5) or ten or more
(C10) coughs during the 1-min period between each dose was
registered. A value of 1024 mmol/L capsaicin was assigned if
C5 and/or C10 values were >512 mmol/L.
Spirometry
Spirometry was performed to measure inspiratory and
expiratory respiratory flow volumes, using a MasterScope
(version 4.67 software, Viasys Healthcare GmbH, Hoech-
berg, Germany). It was done before each provocation, after
menthol inhalation and after the completed capsaicin
provocation. The participants, using a nose-clip, were
instructed to take two normal breaths, then slowly exhale
maximally; slowly inhale maximally; exhale as deeply as
possibly; and then finally inhale as deeply and completely
as possibly.
Statistical analysis
The ManneWhitney U-test was used for non-paired data
and the Wilcoxon signed-rank test was used for paired data.
Data are presented as means with 95% confidence intervals
(CIs) or medians. Results were considered significant if
P < 0.05. All data were analysed using version 16.0 of the
SPSS software package (SPSS, Inc., Chicago, IL, USA).Results
All participants performed the three provocations accord-
ing to the protocol.
Capsaicin cough thresholds
As shown in Table 2, patients’ capsaicin cough thresholds
were significantly lower than the control subjects’ on all
three provocation occasions (P < 0.0001).
After inhalation of 1% menthol, the patients’ C10 cough
thresholds were significantly higher compared to thresholds
after placebo inhalation (P < 0.02) and in comparison to the
thresholds after inhalation of 0.5% menthol (P < 0.05)
(Fig. 1). The C5 was not significantly changed. The cough
thresholds after the inhalation of 0.5% menthol did not
differ significantly from those after placebo inhalation
(0.05% menthol).
The capsaicin cough threshold values of the control
group showed no significant differences after each of the
three inhalations (Table 2).
Table 2 Capsaicin concentration (mmol/L) causing C5 and
C10 in 14 patients with SHR and 15 control subjects.
Capsaicin provocations were preceded by either inhalation
of 1 mL solution of 0.05% menthol, 0.5% menthol or 1%
menthol. Data are presented as medians (mmol/L capsaicin)
with ranges from the 25th to the 75th percentile.
Patients Controls
Pre-inhalation 0.05% menthol (placebo)
C5 4 (2e10) 1024
(32e1024)
C10 8 (3.5e32) 1024
(1024e1024)
Pre-inhalation 0.5% menthol
C5 4 (1.8e8) 512
(512e1024)
C10 6 (4e56) 1024
(1024e1024)
Pre-inhalation 1% menthol
C5 4 (2e14) 1024
(1024e1024)
C10 32 (8e224) 1024
(1024e1024)
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Expiratory values
The mean value of forced expiratory volume in 1 s (FEV1)
before the placebo provocation was 103% of predicted value
(95% CI: 94e112) among the patients and 101% of predictedFigure 1 Box plot presentation showing the log capsaicin
concentration eliciting 5 or 10 or more coughs in 14 patients
with chronic cough after pre-inhalation of either 0.05%
(placebo), 0.5% or 1% menthol. The horizontal line in centre of
each box is the median. The top and bottom of the box
represent the 25th and 75th percentiles, and whiskers indicate
the 10th and 90th percentiles.value (95% CI: 95e108) among the controls (ns). It did not
differ significantly between recordings before or after any of
the provocations (data not shown) in either group.
Inspiratory values
Before inhalation of menthol or placebo the inspiratory
values from the three provocation occasions did not differ
significantly among the patients or the controls or between
the two groups.
After inhalation of placebo there was a significant fall in
peak inspiratory flow (PIF) in the patient group from a mean
value of 3.7 L/s (95% CI: 2.8e4.6) to 3.3 L/s (95% CI: 2.6e4.1)
(P< 0.05). Therewas also a fall in forced inspiratory flow 50%
(FIF50) from 3.5 L/s (95% CI: 2.6e4.5) to 3.1 L/s (95% CI:
2.4e3.9) (P < 0.05) (Fig. 2). After inhalation of 1 mL 0.5%
menthol, the patients’ mean FIF50 decreased significantly
from 3.7 L/s (95% CI: 2.6e4.8) to 3.3 L/s (95% CI: 2.4e4.3)
(P < 0.05) but their PIF values did not change significantly.
Inhalation of 1 mL 1% menthol was not followed by any
significant changes. None of the capsaicin challenges was
followed by any significant changes of inspiratory flows.
Among the controls, the mean FIF50 decreased signifi-
cantly from 4.3 L/s (95% CI: 3.2e5.4) (P < 0.05) to 3.8 L/s
(95% CI: 2.7e4.8) after the placebo inhalation (Fig. 2) but
the PIF values did not change significantly. There were no
significant changes after inhalation of 0.5% or 1% menthol.
None of the capsaicin challenges was followed by any
significant changes of inspiratory flows.
Discussion
The main finding of this study was that in patients with
chronic cough, capsaicin cough thresholds were significantlyFigure 2 Mean changes (L/s) of FIF50 (95% CI) after inha-
lation of placebo (1 mL 0.9% saline with 0.05% menthol) or 1 mL
of 1% menthol in 14 patients with chronic cough and in 15
control subjects.
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placebo inhalation. The placebo inhalationwas also followed
by reduced inspiratory flows both in chronic cough patients
and in control subjects whereas no comparable reduction of
was seen after inhalation of 1% menthol solution.
Capsaicin (8-methyl-N-vanillyl-6-nonenamide) stimulates
the nonmyelinated C-fibre endings of the sensory nervous
system via the transient receptor potential vanilloid subtype
1 (TRPV1) and causes depolarisation across the nerve cell
membrane and a local release of neuropeptides.24 There is
mounting evidence that TRPV1 regulation is complex and
that modulation of selected TRP ion channels may have
beneficial effects at targeting key features of different
respiratory diseases including airways inflammation, airways
hyperreactivity, mucus secretion and cough.16,25 Menthol,
acting via the TRPM8,might interferewith the TRPV1 and the
cough outcome from capsaicin.16 Cough provocation with
capsaicin has, in several studies, shown good reproducibility
in healthy subjects and in patients with cough induced by
environmental irritants26e28 which indicates that the influ-
ence ofmenthol on capsaicin cough sensitivity in this study is
of significance. None of the capsaicin challenges was fol-
lowed by any significant changes of inspiratory flows. There
are only few reports of corresponding studies on inspiratory
flows but this supports earlier findings of Ryan and Gibson29
but is different to what Cho et al. reported.30
Neuro-modulators for sensory neuropathic cough and
new compounds to block TRP receptors hold promise for
chronic cough and airway hypersensitivity.9,16 There is
a rich choice of over-the-counter medications based on
menthol oil. Not least, there are menthol-based prepara-
tions for different airway symptoms, though few scientific
studies can confirm measurable effects. Sant’Ambrogio
et al. showed in1991 that menthol stimulated laryngeal
cold receptors in the absence of cold air31 and in 1994
Morice et al. showed that in healthy subjects cough sensi-
tivity to citric acid was reduced when the citric acid prov-
ocation was preceded by inhalation of menthol.32 Laude
et al. demonstrated corresponding results in guinea pigs.33
Nishino et al. found that nasal inhalation of L-menthol
reduced the sensation of respiratory discomfort associated
with loaded breathing34 whereas on the other hand, Kenia
et al. reported no difference in cough count in children
after inhalation of menthol compared to after inhalation of
a placebo.35 Inhalation of a 1% menthol solution in the
premedication of fiberoptic bronchoscopy did not reduce
the cough counts during the procedure but significantly
increased the peak expiratory flows and reduced cough and
dyspnoea reported by the patients on the day after the
bronchoscopy.36 In a recent study Wise et al. report of
increased capsaicin cough thresholds in healthy subjects
after inhalation from an open bottle containing menthol.37
That study differs from the herein presented results where
we found no effects on capsaicin cough sensitivity in the
control group. Further, in the present study the menthol
was nebulised and given in a randomized and double-blind
order. To our knowledge, no comparable studies have
been done regarding cough patients. There are reports on
the menthol effects (or lack of effects) on nasal airway
resistance35,38 where the findings do not indicate any
objective changes but a subjective sensation of relief and
increased nasal airflow after inhalation of menthol. Thenew findings that the TRPM8 receptor is signalling
increasing mucin secretion, which may be protective, could
account for the decreased capsaicin sensitivity by pre-
venting capsaicin access to the epithelium.39
The findings in this study that inhalation of 1% menthol
was not followed by the same decrease of inspiratory flows
provoked by physiologic saline inhalation may be one
explanation of the benefit that menthol seems to induce in
the airways. Earlier studies have shown a close connection
between chronic cough, laryngeal dysfunction, and extra
thoracic airway hyperresponisveness induced by hypertonic
saline challenge and resulting in decreased inspiratory
flows.29,40 The current results, though assessed by isotonic
saline, are in line with these reports but need to be
confirmed in future studies with a greater number of
participants. However, since there are no international
established guidelines and predicted values for inspiratory
flows, it may be problematic to interpret the outcome.
We conclude that in patients with chronic cough that is
not caused by asthma, COPD or infections, pre-inhalation of
menthol reduces cough sensitivity to inhaled capsaicin and
influences inspiratory flows. The common practice of using
menthol as a reliever for various airway discomforts may
have scientific support in these findings but greater studies
are needed to confirm the results. The use of menthol in
different cigarette brands could be questioned since it
could conceal the natural irritation following smoking.
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